133 related articles for article (PubMed ID: 21300445)
21. Cyclin D1 amplification and p16(MTS1/CDK4I) deletion correlate with poor prognosis in head and neck tumors.
Namazie A; Alavi S; Olopade OI; Pauletti G; Aghamohammadi N; Aghamohammadi M; Gornbein JA; Calcaterra TC; Slamon DJ; Wang MB; Srivatsan ES
Laryngoscope; 2002 Mar; 112(3):472-81. PubMed ID: 12148857
[TBL] [Abstract][Full Text] [Related]
22. Cyclin D1 overexpression in Spitz nevi: an immunohistochemical study.
Nagasaka T; Lai R; Medeiros LJ; Brynes RK; McCourty A; Harada T; Saddik M
Am J Dermatopathol; 1999 Apr; 21(2):115-20. PubMed ID: 10218669
[TBL] [Abstract][Full Text] [Related]
23. Additional Cyclin D(1) gene copies associated with chromosome 11 aberrations in cutaneous malignant melanoma.
Utikal J; Udart M; Leiter U; Peter RU; Krähn G
Int J Oncol; 2005 Mar; 26(3):597-605. PubMed ID: 15703813
[TBL] [Abstract][Full Text] [Related]
24. Patterns of melastatin mRNA expression in melanocytic tumors.
Deeds J; Cronin F; Duncan LM
Hum Pathol; 2000 Nov; 31(11):1346-56. PubMed ID: 11112208
[TBL] [Abstract][Full Text] [Related]
25. Homogeneous staining regions for cyclin D1, a marker of poor prognosis in malignant melanoma.
Gammon B; Ali L; Guitart J; Gerami P
Am J Dermatopathol; 2012 Jul; 34(5):487-90. PubMed ID: 22456513
[TBL] [Abstract][Full Text] [Related]
26. Proteins involved in pRb and p53 pathways are differentially expressed in thin and thick superficial spreading melanomas.
de Sá BC; Fugimori ML; Ribeiro Kde C; Duprat Neto JP; Neves RI; Landman G
Melanoma Res; 2009 Jun; 19(3):135-41. PubMed ID: 19369901
[TBL] [Abstract][Full Text] [Related]
27. Reduced p16 and increased cyclin D1 and pRb expression are correlated with progression in cutaneous melanocytic tumors.
Karim RZ; Li W; Sanki A; Colman MH; Yang YH; Thompson JF; Scolyer RA
Int J Surg Pathol; 2009 Oct; 17(5):361-7. PubMed ID: 19666944
[TBL] [Abstract][Full Text] [Related]
28. Concurrent Ki-67 and p53 immunolabeling in cutaneous melanocytic neoplasms: an adjunct for recognition of the vertical growth phase in malignant melanomas?
Kaleem Z; Lind AC; Humphrey PA; Sueper RH; Swanson PE; Ritter JH; Wick MR
Mod Pathol; 2000 Mar; 13(3):217-22. PubMed ID: 10757331
[TBL] [Abstract][Full Text] [Related]
29. Cdc7 expression in melanomas, Spitz tumors and melanocytic nevi.
Clarke LE; Fountaine TJ; Hennessy J; Bruggeman RD; Clarke JT; Mauger DT; Helm KF
J Cutan Pathol; 2009 Apr; 36(4):433-8. PubMed ID: 19278428
[TBL] [Abstract][Full Text] [Related]
30. [Expression of galanin in melanocytic tumors].
Gilaberte Y; Vera J; Coscojuela C; Roca MJ; Parrado C; González S
Actas Dermosifiliogr; 2007; 98(1):24-34. PubMed ID: 17374330
[TBL] [Abstract][Full Text] [Related]
31. Overexpression of cyclin D1 and cortactin is primarily independent of gene amplification in salivary gland adenoid cystic carcinoma.
Greer RO; Said S; Shroyer KR; Marileila VG; Weed SA
Oral Oncol; 2007 Sep; 43(8):735-41. PubMed ID: 17113340
[TBL] [Abstract][Full Text] [Related]
32. Extra c-myc oncogene copies in high risk cutaneous malignant melanoma and melanoma metastases.
Kraehn GM; Utikal J; Udart M; Greulich KM; Bezold G; Kaskel P; Leiter U; Peter RU
Br J Cancer; 2001 Jan; 84(1):72-9. PubMed ID: 11139316
[TBL] [Abstract][Full Text] [Related]
33. S100A6 protein expression is different in Spitz nevi and melanomas.
Ribé A; McNutt NS
Mod Pathol; 2003 May; 16(5):505-11. PubMed ID: 12748257
[TBL] [Abstract][Full Text] [Related]
34. Malignant melanoma with monster cells showing massive cyclin D1 amplification.
Pouryazdanparast P; Newman M; Mafee M; Guitart J; Gerami P
Am J Dermatopathol; 2009 Jun; 31(4):402-3. PubMed ID: 19461251
[No Abstract] [Full Text] [Related]
35. bcl-2 protein expression in melanocytic neoplasms of the skin.
Ramsay JA; From L; Kahn HJ
Mod Pathol; 1995 Feb; 8(2):150-4. PubMed ID: 7777475
[TBL] [Abstract][Full Text] [Related]
36. Numerical abnormalities of the Cyclin D1 gene locus on chromosome 11q13 in non-melanoma skin cancer.
Utikal J; Udart M; Leiter U; Kaskel P; Peter RU; Krähn G
Cancer Lett; 2005 Mar; 219(2):197-204. PubMed ID: 15723720
[TBL] [Abstract][Full Text] [Related]
37. Fluorescence in situ hybridization as an ancillary method for the distinction of desmoplastic melanomas from sclerosing melanocytic nevi.
Gerami P; Beilfuss B; Haghighat Z; Fang Y; Jhanwar S; Busam KJ
J Cutan Pathol; 2011 Apr; 38(4):329-34. PubMed ID: 21323721
[TBL] [Abstract][Full Text] [Related]
38. EMS1 gene expression in primary breast cancer: relationship to cyclin D1 and oestrogen receptor expression and patient survival.
Hui R; Ball JR; Macmillan RD; Kenny FS; Prall OW; Campbell DH; Cornish AL; McClelland RA; Daly RJ; Forbes JF; Blamey RW; Musgrove EA; Robertson JF; Nicholson RI; Sutherland RL
Oncogene; 1998 Aug; 17(8):1053-9. PubMed ID: 9747885
[TBL] [Abstract][Full Text] [Related]
39. Distinction of conjunctival melanocytic nevi from melanomas by fluorescence in situ hybridization.
Busam KJ; Fang Y; Jhanwar SC; Pulitzer MP; Marr B; Abramson DH
J Cutan Pathol; 2010 Feb; 37(2):196-203. PubMed ID: 20100177
[TBL] [Abstract][Full Text] [Related]
40. Development of a novel noninvasive adhesive patch test for the evaluation of pigmented lesions of the skin.
Gerami P; Alsobrook JP; Palmer TJ; Robin HS
J Am Acad Dermatol; 2014 Aug; 71(2):237-44. PubMed ID: 24906614
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
